Cend Therapeutics

Delivering more effective  anticancer drugs

The leading platform for targeted drug delivery

Effectively treating solid tumor cancers

Cend Therapeutics is a clinical-stage biotech company focused on a novel approach to provide more effective treatments for solid tumor cancer patients.

About Us

Pancreatic

Breast

Gastric

OUR

PIPELINE

Liver

Lung

Brain

Learn More

Latest News

June 9, 2022

Cend Therapeutics Announces First Patient Treated in Phase 2b Trial of CEND-1 led by Australasian Gastro-Intestinal Trials Group

OUR

SCIENCE

PARTNERS AND
INVESTORS

Cend and our investors are committed to delivering better therapies for a range of solid tumor cancer patients. We work with partners who are leaders in their fields to help them better address cancers for the patients they serve.